Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
761-780 of 1,743 trials

Radiprodil for Children with GRIN-related Disorder

We are studying a new medication to see if it is safe and helps reduce seizures and improve behavior in children with GRIN-related disorder. This trial aims to find the right dose and understand its effects over time.

GRIN-related Disorder>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesNeurologyPediatrics

High-Risk Neuroblastoma: Dinutuximab Beta with Chemotherapy

We are studying the safety and effectiveness of combining dinutuximab beta with two chemotherapy regimens for children with newly diagnosed high-risk neuroblastoma. This research aims to improve treatment options and outcomes for these young patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Atrial Fibrillation: New Drug Treatment After Stent Surgery

We are studying whether a simpler medication regimen can safely prevent blood clots and serious heart issues in patients with irregular heartbeat after coronary stent implantation. This trial compares it to the current standard treatment involving multiple medications.

Acute Coronary SyndromeAtrial FibrillationAtrial Flutter>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

CART Cell Therapy for Acute Lymphoblastic Leukemia in Young Patients

We are studying the safety and feasibility of new CART cell therapies for children and young adults with relapsed or refractory acute lymphoblastic leukemia. This trial aims to find better treatment options for those who have not responded to current therapies.

Acute Lymphoblastic Leukemia (ALL)>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Metastatic Colorectal Cancer: Regorafenib with Chemotherapy

We are studying whether combining Regorafenib with metronomic chemotherapy and low-dose aspirin helps patients with chemo-resistant metastatic colorectal cancer live longer without disease progression. We will also look at quality of life and treatment side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Advanced PRAME Positive Cancers: IMC-P115C Treatment

We are testing a new treatment called IMC-P115C for patients with advanced cancers that are PRAME positive. This study aims to evaluate the safety and appropriate dosage of this new therapy.

Clear Cell Endometrial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Severe von Willebrand Disease: New Treatment Study

We are testing a new treatment for children with severe von Willebrand Disease to see if it helps control bleeding episodes and is safe during surgeries. The study will compare this treatment with and without an existing medication.

Von Willebrand's Factor Deficiency>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Pain Management in Heart Surgery: Interpectoral-Pectoserratus Block

We are studying a new pain relief technique for patients undergoing minimally invasive aortic valve replacement. The goal is to see if it improves pain control and recovery compared to a standard approach.

Aortic Valve Disease>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCardiologyOtolaryngology

Localized Prostate Cancer: Darolutamide and Radiation Therapy

We are studying the effects of darolutamide with or without radiation therapy in patients with localized prostate cancer at high risk of relapse. The goal is to see if this combination improves survival and quality of life.

Localized Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: JAK Inhibitor Dose Tapering Study

We are exploring whether reducing the dose of JAK inhibitors helps maintain low disease activity in rheumatoid arthritis patients. This study will also look at the impact on pain, function, and overall quality of life.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesRheumatology

Ibrutinib for Autoimmune Hemolytic Anemia in CLL Patients

We are studying whether ibrutinib can effectively treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia or similar conditions. The trial will also look at the safety and quality of life during treatment.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

De-escalating Treatment for HER2-Positive Metastatic Breast Cancer

We are studying whether reducing treatment is safe for patients with undetectable cancer levels after long-term therapy. This trial aims to assess the impact on survival and quality of life.

HER2-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Rhinosinusitis with Nasal Polyps: Dupilumab Study

We are exploring how Dupilumab may improve nasal barrier function in patients with Chronic Rhinosinusitis with nasal polyps. This study compares the effects of treatment on nasal cells from patients and healthy controls.

Chronic Rhinosinusitis with Nasal PolypsChronic Rhinosinusitis without Nasal Polyps>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

Testosterone Supplementation for Obese Men with Type 2 Diabetes

We are studying whether intramuscular testosterone can reduce liver fat in obese men with low testosterone and type 2 diabetes. This trial will also look at the long-term effects on metabolic health.

HypogonadismType 2 Diabetes Mellitus (T2DM)Prediabetes>2 yearsMonitoring phase (IV)Post-Trial Drug AccessInvestigational MedicinesDiabetologyEndocrinologyInternal Medicine

Diabetic Macular Edema: Faricimab Treatment Study

We are exploring whether Faricimab can improve vision in patients with diabetic macular edema. The study also examines changes in eye health and treatment frequency over 12 months.

Diabetic Macular Edema>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyOphthalmology

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Cancers: BI-1808 Monoclonal Antibody

We are studying a new treatment called BI-1808 for people with advanced cancers, both alone and with pembrolizumab. The goal is to assess its safety and how well it is tolerated by patients.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Colon Cancer: Personalized Treatment Strategy

We are exploring whether a blood-based genomic approach can improve outcomes for patients with operable Stage III and high-risk Stage II colon cancer compared to standard chemotherapy. This study also looks at side effects and quality of life.

Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

Diffuse Large B-cell Lymphoma: Loncastuximab and Epcoritamab Study

We are studying a combination of two medications for patients with relapsed or refractory diffuse large B-cell lymphoma. The goal is to see how well this treatment works and its safety compared to existing options.

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL) Grade 3BHigh-Grade B-Cell Lymphoma (HGBL)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology